ImmunityBio, Inc. IBRX Non-cash interest expense related to revenue interest liability
Non-cash interest expense related to revenue interest liability at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept ibrx:InterestExpenseNonoperatingSecuredDebtNet.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s non-cash interest expense related to revenue interest liability.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s non-cash interest expense related to revenue interest liability?
- ImmunityBio, Inc. (IBRX) reported non-cash interest expense related to revenue interest liability of $8.32M in Q1 2026.
- How has ImmunityBio, Inc.'s non-cash interest expense related to revenue interest liability changed year-over-year?
- ImmunityBio, Inc.'s non-cash interest expense related to revenue interest liability decreased by 37.3% year-over-year, from $13.27M to $8.32M.
- What does non-cash interest expense related to revenue interest liability mean?
- This represents the non-cash interest expense accrued on debt instruments tied to future revenue streams or specific financing arrangements. It reflects the cost of capital that does not involve an immediate cash outflow, often arising from complex debt structures common in biotechnology financing.